ACM
CLYM

ADAR1 Capital Management’s Climb Bio CLYM Stock Holding History

ADAR1 Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Buy
822,649
+224,987
+38% +$2.32M 0.49% 48
2026
Q1 		$4.09M Sell
597,662
-834,813
-58% -$4.82M 0.24% 88
2025
Q4 		$5.73M Buy
1,432,475
+1,298,945
+973% +$3.12M 0.42% 53
2025
Q3 		$268K Buy
133,530
+14,210
+12% +$26.4K 0.03% 168
2025
Q2 		$148K Hold
119,320
– – 0.02% 163
2025
Q1 		$146K Buy
119,320
+71,195
+148% +$115K 0.03% 155
2024
Q4 		$86.6K Sell
48,125
-115,318
-71% -$417K 0.02% 183
2024
Q3 		$832K Buy
163,443
+65,748
+67% +$465K 0.14% 88
2024
Q2 		$695K Buy
+97,695
New +$650K 0.13% 83

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ADAR1 Capital Management's CLYM Position: Q2 2026 in Review

ADAR1 Capital Management increased its Climb Bio (CLYM) stake by 38% in Q2 2026, buying an estimated $2.32M and bringing the position to 822,649 shares worth $10.7M. The position accounts for 0.49% of the portfolio, ranked #48.

ADAR1 Capital Management first reported a position in CLYM in Q2 2024 and has held it in 9 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • ADAR1 Capital Management held 822,649 shares of Climb Bio worth $10.7M as of Q2 2026.
  • ADAR1 Capital Management bought 224,987 Climb Bio shares in Q2 2026, an estimated $2.32M.
  • Climb Bio made up 0.49% of ADAR1 Capital Management's portfolio in Q2 2026, its #48 holding.
  • ADAR1 Capital Management first reported a position in Climb Bio in Q2 2024 and has held it in 9 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.